Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05985642 · ClinicalTrials.gov registry record
Observational PIC Destination Cohort
A clinical trial of HIV-1-infection, sponsored by Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections.
- Recruiting
- Registry status
- 30
- Enrollment target
- 4
- Study locations
NCT05985642: Recruiting study of HIV-1-infection, sponsored by Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections.
NCT05985642 is a study of HIV-1-infection that is actively recruiting participants, run by Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections. The registered enrollment target is 30 participants, below the 351-participant average among 71 other HIV-1-infection trials with a reported enrollment target (91% lower). The trial reports 4 study locations across 4 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05985642, a study of HIV-1-infection, is actively recruiting participants, sponsored by Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections.
- RECRUITING
- Registry status
- 30 participants
- Enrollment target
- 4
- Study locations
Study Summary
This study is being done to see if people who control HIV without antiretroviral therapy (ART) after receiving an intervention can remain off ART safely. The information collected in this study is also being used to try to understand how people control HIV without ART after receiving an intervention.
Primary Outcome
The proportion of participants reporting a serious adverse event (SAE) or a grade ≥ 3 adverse event (AE) that was judged by the A5385 clinical management committee to be at least possibly related to ATI during Step 1. An AE is any unfavorable and unintended sign, symptom, or diagnosis occurring in a study participant during the conduct of the study regardless of the attribution. An SAE is any untoward medical occurrence that results in death; is life-threatening; requires inpatient hospitalizat
Conditions Studied
Study Locations (4)
California
- University of California, San Francisco HIV/AIDS CRS (801) - San Francisco
Missouri
- Washington University Therapeutics (WT) CRS (2101) - St Louis
New York
- Weill Cornell Upton CRS (7803) - New York
Ohio
- Case CRS (2501) - Cleveland
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2024-03-19 |
| Est. Completion | 2029-09-03 |
What NCT05985642 shows while recruiting
NCT05985642 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 30 participants, a relatively small participant target, below the 351-participant average among 71 other HIV-1-infection trials with a reported enrollment target (91% lower).
The record links to 1 condition, with HIV-1-infection appearing as the primary indexed condition, and to 0 interventions.
NCT05985642 reports a single indexed study location in California, Missouri, New York.
Frequently Asked Questions
What is clinical trial NCT05985642 about?
NCT05985642 is a clinical study titled "Observational PIC Destination Cohort". This study is being done to see if people who control HIV without antiretroviral therapy (ART) after receiving an intervention can remain off ART safely. The information collected in this study is also being used to try to understand how people control HIV without ART after receiving an intervention...
What is the current status of trial NCT05985642?
This trial is currently recruiting. The enrollment target is 30 participants. The study started on 2024-03-19. Estimated completion is 2029-09-03.
What conditions does trial NCT05985642 study?
This clinical trial studies the following conditions: HIV-1-infection.
Who is sponsoring clinical trial NCT05985642?
This trial is sponsored by Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections, which has 45 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05985642 being conducted?
This trial has 4 study locations across California, Missouri, New York, Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for HIV-1-infection
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05985642's enrollment target sits among peer trials
30 58th of 71 higher than 12 of 71 other HIV-1-infection trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other HIV-1-infection trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Improving Coronary Vascular Health in Women
RECRUITING · Phase 2
-
Study of GS-3242 in Participants With HIV-1; Substudy-05
RECRUITING · Phase 1
-
Acceptance and Commitment Therapy for HIV+ Hazardous Drinkers
RECRUITING · NA
-
Understanding Practices of Lactation and Infant Feeding Together With Women With HIV in the United States
RECRUITING
-
Ending the Epidemic Interventions in the Dental Setting - UH3
RECRUITING · NA
-
Tesamorelin as an Adjunct to Exercise for Improving Physical Function in HIV
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00977977 · 30 participants · Phase 2
Rituximab Plus Cyclosporine in Idiopathic Membranous Nephropathy
- NCT01459107 · 30 participants · Phase 2
Human Upper Extremity Allotransplantation
- NCT01666080 · 30 participants · NA
Second or Greater Allogeneic Hematopoietic Stem Cell Transplant Using Reduced Intensity Conditioning (RIC)
- NCT01720836 · 30 participants · Phase 1
Study of the Immune Response of MUC1 (Mucin1) Peptide Vaccine for Non-small Cell Lung Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI